You are here:

emtricitabine/tenofovir alafenamide (Descovy)

Advice

following an abbreviated submission:

emtricitabine/tenofovir alafenamide (Descovy®) is accepted for use within NHS Scotland.

Indication under review: in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.

For adult patients in whom emtricitabine/tenofovir is an appropriate combination, Descovy® (emtricitabine/tenofovir alafenamide) offers an alternative to Truvada® (emtricitabine/ tenofovir disoproxil) at no additional cost, and may also be used in patients from 12 years of age.

Drug Details

Drug Name: emtricitabine/tenofovir alafenamide (Descovy)
SMC Drug ID: 1169/16
Manufacturer: Gilead Sciences Ltd
Indication: In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 August 2016

Back